Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT03403127 Active, not recruiting - Lung Cancer Clinical Trials

PET CT Re-Planning NSCLC (4DCT-PET)

Start date: May 20, 2008
Phase: N/A
Study type: Interventional

This study will see whether the addition of more frequent planning CTs during the course of radiation, and of Positron Emission Tomography (PET), a diagnostic test similar to CT, prior to and during a course of radiation may provide information that could potentially be used during the treatment to improve the initial radiation plan.

NCT ID: NCT03399669 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Start date: February 17, 2015
Phase: Phase 2
Study type: Interventional

Although EGFR-TKIs such as gefitinib, erlotinib or afatinib are recommended as first-line therapy in patients with advanced, recurrent or metastatic nonsquamous NSCLC patients who have known active EGFR mutation and achieved response to EGFR TKIs experience disease progression eventually with 10-14 moths of median progression free survival.6 Platinum-doublets combination chemotherapy remains standard of care for patients with progressive disease. However, patients may derive benefit from EGFR TKIs after RECIST-assessed progression especially for those who experience slow progression. And previous report suggested that premature discontinuation of EGFR TKIs has resulted in rapid progression in symptoms and tumor growth.7 Recently, a prospective phase II single arm study in Asian patients with EGFR mutation-positive NSCLC to determine the continuation of erlotinib beyond progression judged by investigators showed that additional PFS of 3.1 months can be achieved with continuation of erlotinib without serious additional toxicities.8 Until now, no prospective study has been conducted for gefitinib. In this study the continuation of gefitinib beyond RECIST progression will be investigated to determine the clinical outcomes including the duration of treatment and safety. This is a single-arm phase II trial to evaluate the efficacy and safety of continuation of gefitinib in EGFR mutant NSCLC patients who experience RECIST progression. Based on the results of "ASPIRATION" study, the median PFS for continuation of gefitinib will be around 3 months. The study treatment will be of no interest if the true median PFS is 2.5 months or shorter. In contrast, it will be of interest if the true median PFS is 3.5 months or longer. Considering 1 sided alpha of 0.05 and 90% of power, 95 patients are required. A total of 100 patients will be needed considering 5% of drop-out rate. 6 months of accrual and additional 6 months of follow-up will be assumed for this study. Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.

NCT ID: NCT03396497 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

Start date: January 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1B study designed to assess the safety and tolerability of LYC-55716 given in combination with pembrolizumab to subjects with metastatic NSCLC, and to assess the combination for biologic and clinical activity in NSCLC.

NCT ID: NCT03392246 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Start date: January 31, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of two targeted therapies as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The drugs involved in this study are: - Osimertinib (Tagrisso) - Selumetinib

NCT ID: NCT03392233 Recruiting - Breast Cancer Clinical Trials

Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors

Start date: August 18, 2017
Phase: Phase 2
Study type: Interventional

Stereotactic Body Radiation Therapy(SBRT) for spinal metastases has been proved a good results in pain relieve and local control, However,the longterm of efficacy and safety of this regimen is unclear.The purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be survival more than 2 years.

NCT ID: NCT03391869 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR)

Start date: December 29, 2017
Phase: Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if local consolidation treatment (LCT-- surgery and/or radiation) plus standard chemotherapy (ipilimumab and nivolumab) is more effective than ipilimumab and nivolumab alone in treating patients with metastatic (has spread) non-small cell lung cancer (NSCLC) who have not previously received immunotherapy. This is an investigational study. LCT is FDA approved and commercially available for the treatment of NSCLC. Nivolumab and ipilimumab are FDA approved and commercially available for treatment of many types of cancer. It is considered investigational to use nivolumab and ipilimumab to treat metastatic NSCLC. The study doctor can explain how the study drugs and LCT are designed to work. Up to 270 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT03390686 Not yet recruiting - Lung Cancer Clinical Trials

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenecity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Start date: January 2018
Phase: Phase 3
Study type: Interventional

In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy, safety, pharmacokinetics and immunogenecity.

NCT ID: NCT03389399 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC

Start date: January 30, 2018
Phase: N/A
Study type: Observational

To estimate the incidence of Early Onset Pulmonary Events (EOPEs), defined as the proportion of participants with a peak reduction in DLCO of 20% or greater after commencing brigatinib at 90mg QD.

NCT ID: NCT03386955 Recruiting - Clinical trials for Non-small Cell Lung Cancer

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Start date: August 16, 2017
Phase: Phase 1
Study type: Interventional

Lung cancer has the highest incidence rate in China and is also a very common cancer in the world. BPI-7711 is a potential new drug developed for advanced or recurrent non-small cell lung cancer. The purpose of this study is to evaluate the safety, efficacy and how the drug is used by the body. The first part of the study will recruit 3~6 patients for different dose levels to evaluate safety. The dose will increase from the lowest level. In the first part, the study will also collect data on how the drug is used by the body to better decide how the drug should be taken. The second part of the study is the expansion part. Once efficacy is observed in the dose increasing process, additional 20~30 patients will be enrolled to further evaluate the anti-tumor efficacy of each dose level. Estimate 50~80 patients will be enrolled for both part. A recommended dose will be selected for Phase II study.

NCT ID: NCT03384511 Recruiting - Breast Cancer Clinical Trials

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Start date: September 30, 2016
Phase: Phase 4
Study type: Interventional

This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 PET/CT scan can predict the efficacy and adverse events of apatinib in patients with malignancies. Integrin αvβ3 has been shown to play an important role in angiogenesis and up-regulated obviously in various types of tumor cells and activated endothelial cells. The arginine-glycine-aspartic acid (RGD) tripeptide sequence can bind to integrin αvβ3 with high affinity and specificity. The 18F-ALF-NOTA-PRGD2 will highly combine with αvβ3, and thus will monitor the antiangiogenic status.In the current study, investigators propose to evaluate the feasibility of 18F-RGD PET/CT in monitoring efficacy and adverse events of apatinib in malignancies.